The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 26, 2018
Filed:
May. 09, 2016
Gilead Sciences, Inc., Foster City, CA (US);
Peter A. Blomgren, Issaquah, WA (US);
Jayaraman Chandrasekhar, Redmond, WA (US);
Kevin S. Currie, North Bend, WA (US);
Zhimin Du, Belmont, CA (US);
Julie Farand, San Mateo, CA (US);
Juan A. Guerrero, Clayton, CA (US);
Ashley A. Katana, North Olmsted, OH (US);
Darryl Kato, San Francisco, CA (US);
Jeffrey E. Kropf, Issaquah, WA (US);
Scott E. Lazerwith, Burlingame, CA (US);
Seung H. Lee, Sammamish, WA (US);
Jiayao Li, Foster City, CA (US);
John O. Link, San Francisco, CA (US);
Jennifer R. Lo, Seattle, WA (US);
Nicholas Mai, Marriottsville, MD (US);
Scott A. Mitchell, Kenmore, WA (US);
Gregory Notte, Redwood City, CA (US);
Hyung-jung Pyun, Fremont, CA (US);
Michael Sangi, San Mateo, CA (US);
Aaron C. Schmitt, Hamden, CT (US);
Adam J. Schrier, Redwood City, CA (US);
Kirk L. Stevens, Bothell, WA (US);
Chandrasekar Venkataramani, San Carlos, CA (US);
William J. Watkins, Saratoga, CA (US);
Jin-Ming Xiong, Guilford, CT (US);
Jianjun Xu, Bellevue, WA (US);
Zheng-Yu Yang, Palo Alto, CA (US);
Jeff Zablocki, Los Altos, CA (US);
Zhongdong Zhao, Bellevue, WA (US);
Sheila Zipfel, San Mateo, CA (US);
Gilead Sciences, Inc., Foster City, CA (US);
Abstract
The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, X, X, R, R, R, R, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.